Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
NCT07536789Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of becotatug vedotin in hepatocellular carcinoma (HCC), sponsored by Fudan University. Primary endpoint: Objective Response Rate in Cohort 1 at 24 months. Started Apr 2026; status: recruiting.
02
Drugs
becotatug vedotin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07536789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07536789.